Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $15.00 price target by equities researchers at Morgan Stanley in a report issued on Thursday. The brokerage presently has an “underweight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 4.34% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Mizuho raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and boosted their price target for the company from $25.00 to $30.00 in a report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Tuesday, June 27th. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Finally, Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $32.27 price target for the company in a report on Tuesday, July 11th. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average target price of $28.72.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.51% during mid-day trading on Thursday, hitting $15.76. 9,306,582 shares of the stock traded hands. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.85. The stock has a 50-day moving average of $16.94 and a 200 day moving average of $26.89. The firm’s market cap is $16.01 billion. Teva Pharmaceutical Industries Limited also saw some unusual options trading activity on Wednesday. Investors purchased 29,656 put options on the stock. This is an increase of approximately 231% compared to the typical volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm posted $1.25 EPS. The business’s revenue was up 12.9% compared to the same quarter last year. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Morgan Stanley Reiterates $15.00 Price Target for Teva Pharmaceutical Industries Limited (TEVA)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/05/teva-pharmaceutical-industries-limited-teva-pt-lowered-to-15-00.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Capital Research Global Investors increased its holdings in shares of Teva Pharmaceutical Industries Limited by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. increased its holdings in shares of Teva Pharmaceutical Industries Limited by 11.1% in the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries Limited by 16.7% in the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Northern Cross LLC increased its holdings in shares of Teva Pharmaceutical Industries Limited by 14.0% in the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares during the period. Finally, Nordea Investment Management AB increased its holdings in shares of Teva Pharmaceutical Industries Limited by 2.5% in the 2nd quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares during the period. Institutional investors own 56.77% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.